Ultra-Scan's TouchLink Solution Allows CROs to Accurately Identify Patients and Ensure Study Integrity.
Buffalo, NY-June 13, 2006-As federal regulations become stricter, it is important for clinical research organizations (CROs) to take the necessary measurements and precautions to accurately identify study participants and their eligibility for clinical trial participation. Ultra-Scan Corporation, an identity management solutions provider, will showcase its TouchLink Identity Management Software at the Drug Information Association's 42nd Annual Meeting in Philadelphia. Researchers and trial administrators will have the opportunity learn more about this revolutionary technology in support of clinical trials.
Ultra-Scan's TouchLink Identity Management Software offers clinical research organizations an accurate and cost-effective solution for establishing, managing and repeatedly validating subject identity. TouchLink provides standalone or integrated identification utilizing Ultra-Scan's patented ultrasonic fingerprint identification system to quickly and easily enroll and identify a subject population within a single site or across multiple sites and facilities. From screening through post-study follow-up, TouchLink can positively impact study results and enhance subject safety by providing essential identity validation. In turn, this ensures that each authorized subject is properly tested, treated, monitored and reimbursed during clinic and study encounters.
TouchLink is supported by Ultra-Scan's patented Livescan Ultrasonic Identification Systems (LUIS™), a biometric technology that uses ultrasound, high frequency sound waves, to capture high quality fingerprint images across all user populations and operational environments. LUIS can "see through" dirt, newsprint, hand lotions and other common finger contaminants, guaranteeing unsurpassed accuracy, reliability and ease of use.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Full Phase IIIb BATURA Trial Results Show Airsupra Cuts Severe Exacerbations by 47% in Mild Asthma
May 20th 2025Results from the pivotal BATURA trial show that Airsupra (albuterol/budesonide) significantly outperformed albuterol monotherapy in reducing severe asthma exacerbations and systemic corticosteroid exposure, reinforcing its role as a next-generation, anti-inflammatory rescue therapy for mild asthma patients.